191 related articles for article (PubMed ID: 24396884)
1. Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Salama JK; Pang H; Bogart JA; Blackstock AW; Urbanic JJ; Hogson L; Crawford J; Vokes EE
Lung Cancer; 2013 Dec; 82(3):436-40. PubMed ID: 24396884
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.
Salama JK; Hodgson L; Pang H; Urbanic JJ; Blackstock AW; Schild SE; Crawford J; Bogart JA; Vokes EE;
J Thorac Oncol; 2013 Aug; 8(8):1043-9. PubMed ID: 23715301
[TBL] [Abstract][Full Text] [Related]
4. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
5. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
6. Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
Barney CL; Scoville N; Allan E; Ayan A; DiCostanzo D; Haglund KE; Grecula J; Williams T; Xu-Welliver M; Otterson GA; Bazan JG
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):748-755. PubMed ID: 29413286
[TBL] [Abstract][Full Text] [Related]
7. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
8. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer.
Bogart JA; Waqar SN; Mix MD
J Clin Oncol; 2022 Feb; 40(6):661-670. PubMed ID: 34985935
[TBL] [Abstract][Full Text] [Related]
9. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
10. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
Stinchcombe TE; Fan W; Schild SE; Vokes EE; Bogart J; Le QT; Thomas CR; Edelman MJ; Horn L; Komaki R; Cohen HJ; Kishor Ganti A; Pang H; Wang X
Cancer; 2019 Feb; 125(3):382-390. PubMed ID: 30343497
[TBL] [Abstract][Full Text] [Related]
11. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
[TBL] [Abstract][Full Text] [Related]
12. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
[TBL] [Abstract][Full Text] [Related]
14. Moderately Hypofractionated Once-Daily Compared With Twice-Daily Thoracic Radiation Therapy Concurrently With Etoposide and Cisplatin in Limited-Stage Small Cell Lung Cancer: A Multicenter, Phase II, Randomized Trial.
Qiu B; Li Q; Liu J; Huang Y; Pang Q; Zhu Z; Yang X; Wang B; Chen L; Fang J; Lin M; Jiang X; Guo S; Guo J; Wang D; Liu F; Chu C; Huang X; Xie C; Liu H
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):424-435. PubMed ID: 33992717
[TBL] [Abstract][Full Text] [Related]
15. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation.
Rutter CE; Park HS; Corso CD; Yeboa DN; Mancini BR; Lester-Coll NH; Kim AW; Decker RH
Lung Cancer; 2015 Nov; 90(2):243-8. PubMed ID: 26277031
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric rationale and early experience at UFPTI of thoracic proton therapy and chemotherapy in limited-stage small cell lung cancer.
Colaco RJ; Huh S; Nichols RC; Morris CG; D'Agostino H; Flampouri S; Li Z; Pham DC; Bajwa AA; Hoppe BS
Acta Oncol; 2013 Apr; 52(3):506-13. PubMed ID: 23438357
[TBL] [Abstract][Full Text] [Related]
17. Sequential Versus Concurrent Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for N3 Limited-Stage Small-Cell Lung Cancer.
Wang Z; Wan J; Liu C; Li L; Dong X; Geng H
Cancer Control; 2020; 27(1):1073274820956619. PubMed ID: 32951452
[TBL] [Abstract][Full Text] [Related]
18. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
[TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for pulmonary complications in patients with limited-stage small cell lung cancer : A single-centre retrospective study.
Sas-Korczyńska B; Łuczyńska E; Kamzol W; Sokołowski A
Strahlenther Onkol; 2017 Feb; 193(2):141-149. PubMed ID: 27785518
[TBL] [Abstract][Full Text] [Related]
20. Penetration of recommended procedures for lung cancer staging and management in the United States over 10 years: a quality research in radiation oncology survey.
Komaki R; Khalid N; Langer CJ; Kong FM; Owen JB; Crozier CL; Wilson JF; Wei X; Movsas B
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1082-9. PubMed ID: 23273996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]